Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDER Eyes Prioritization, Timely Resolution Of Post-Marketing Safety Issues

Executive Summary

Now that it has a system in place to track post-marketing drug safety issues, FDA’s Center for Drug Evaluation and Research is turning its attention to setting standard timeframes for investigating and addressing such signals.

You may also be interested in...

REMS Templates Get Nod From FDA, With Nudge From Pharmacists

At workshop, agency acknowledges efficiency and implementation burdens that the myriad risk management program programs create, but developing a standardized approach will not easy task either.

PhRMA Wants MedGuides Developed The Pre-FDAAA Way, Not Through REMS

Using 1998 authority would reduce the burden on sponsors, physicians and patients, industry group says.

FDA Seeks To Write MedGuides Outside REMS Process

FDA is searching for a way out of imposing a REMS when only a medication guide is required

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts